| Name | Title | Contact Details |
|---|
tgi healthnetworks is a Nyack, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The MBX Difference: Relationship Based Partnerships Our bottom line in your bottom line. We don`t simply chase the low-hanging fruit. Put simply, our outsourced revenue cycle management will collect more dollars, improve your cash flow, support your physicians and delight your patients. MBX is a growing organization specializing in radiology billing. With MBX, from the start of our relationship to go live, you are in safe hands. Our experienced leadership team, who between them possess over seven decades of working with some of the nation’s leading radiology group practices, has implemented over 300 outsourced revenue cycle management systems. We process millions of procedures per year for practices from coast to coast, as diverse as three provider interventional radiologists in Oregon to a 100+ provider practice in North Carolina. MBX delivers consistent and exceptional revenue cycle management. We bill and collect every possible dollar by capitalizing on operational expertise that is second to none. Our exceptional rate of claims accepted the first time, along with our strong denials management process, ensures that claims are processed quickly and denials handled efficiently and effectively. Our end-to-end service extends from the point at which we receive the physician’s dictated report all the way through to the patient’s account at zero balance – we worry about the billing, you lower your operational overheads.
Clinisys is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Maxygen, Inc. (Maxygen) is a biotechnology company engaged in the discovery and development of improved protein pharmaceuticals for the treatment of disease and serious medical conditions.
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.